Cristos Ifantides, MD
Ophthalmology · Denver, CONPI 1821356676
Payments from drug & device makers
Across 388 payments — averaging $3644.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon Research LLC$1.1M
- Tarsus Pharmaceuticals, Inc.$193K
- Alcon$39K
- Bausch & Lomb Americas Inc.$27K
- AbbVie$16K
- Johnson & Johnson Surgical Vision, Inc.$15K
- plus $30K from 20 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon Research LLC | 20 | $1,094,239 |
| Tarsus Pharmaceuticals, Inc. | 38 | $193,419 |
| Alcon | 85 | $38,870 |
| Bausch & Lomb Americas Inc. | 45 | $26,646 |
| AbbVie(2 entities) | 75 | $15,658 |
| Johnson & Johnson Surgical Vision, Inc. | 23 | $14,889 |
| NEW World Medical,inc. | 8 | $6,325 |
| Sight Sciences, Inc. | 14 | $5,934 |
| Carl Zeiss Meditec USA, Inc. | 8 | $4,694 |
| Dompe US, Inc. | 13 | $3,538 |
| Lensar, Inc. | 10 | $3,458 |
| Carl Zeiss Meditec, Inc. | 6 | $3,133 |
| Glaukos Corporation | 16 | $1,099 |
| Beaver-visitec International, Inc. | 1 | $500 |
| Sun Pharmaceutical Industries Inc. | 5 | $426 |
| Microsurgical Technology, Inc. | 1 | $330 |
| Carl Zeiss Meditec Cataract Technology Inc. | 6 | $253 |
| Ocular Therapeutix, Inc. | 3 | $206 |
| Dutch Ophthalmic, USA | 2 | $169 |
| Rayner Intraocular Lenses Limited | 3 | $99 |
| Kala Pharmaceuticals, Inc. | 1 | $46 |
| Novartis | 1 | $42 |
| Omeros Corporation | 1 | $34 |
| Rxsight Inc | 1 | $26 |
| Oyster Point Pharma, Inc. | 1 | $20 |
| Carl Zeiss Meditec AG | 1 | $19 |
How this compares
$1,414,071 in reported general payments places this provider in the 95th percentile of 262 ophthalmology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other ophthalmology in Denver
- Michael JansenDenver$1.8M
- Curtis HagedornDenver$1.5M
- Mark DaceyDenver$798K
- Peter HovlandDenver$568K
- Kingsley OkaforDenver$317K
- Jack ZamoraDenver$172K
- Eva KimDenver$95K
- Michael SolomonDenver$12K
- Matthew KrugerDenver$8K
- Stuart LewisDenver$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.